Asset Details
Do you wish to reserve the book?
Patients must be encouraged to 'Talk Hypos'
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Patients must be encouraged to 'Talk Hypos'
Do you wish to request the book?
Patients must be encouraged to 'Talk Hypos'
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Patients must be encouraged to 'Talk Hypos'
2015
Overview
A Copenhagen native, Klaus Henning Jensen started his career working as a medical doctor in a hospital setting. An entrepreneur at heart, he drew from his background in physics and business administration to co-found a device company - successfully developing a new type of surgical screw for osteosynthesis of hip fractures. Klaus' career at Novo Nordisk spans almost a decade and is rooted in Global Medical Affairs. He has held a series of Medical Director and Vice President roles with responsibilities cutting across the entire Novo Nordisk (UK and Ireland) diabetes portfolio - medical devices, Victoza
(liraglutide), Tresiba
(insulin degludec), Ryzodeg
(insulin degludec/insulin aspart) and Xultophy
(insulin degludec/liraglutide), as well as other GLP-1 and insulin treatments - with medical and scientific responsibility for the R&D of several of these products. He now sits on the UK & Ireland leadership team as Head of Clinical, Medical and Regulatory.
Publisher
Future Medicine Ltd
